Twinkle-associated familial parkinsonism with Lewy pathology:Cause or predisposition? by Breen, David P. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twinkle-associated familial parkinsonism with Lewy pathology
Citation for published version:
Breen, DP, Munoz, DG & Lang, AE 2020, 'Twinkle-associated familial parkinsonism with Lewy pathology:
Cause or predisposition?', Neurology, pp. 10.1212/WNL.0000000000010674.
https://doi.org/10.1212/WNL.0000000000010674
Digital Object Identifier (DOI):
10.1212/WNL.0000000000010674
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Neurology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Sep. 2020
Neurology Publish Ahead of Print
DOI: 10.1212/WNL.0000000000010674
 
 
 
 
 
 
 
 
 
David P Breen, MBChB, PhD1,2,3, David G Munoz, MD MSc4, Anthony E Lang, 
MD5,6,7* 
 
 
The Article Processing Charge was funded by University of Edinburgh Charity Open 
Access Fund. 
 
This is an open access article distributed under the terms of the Creative Commons 
Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
 
Neurology® Published Ahead of Print articles have been peer reviewed and accepted 
for publication. This manuscript will be published in its final form after copyediting, 
page composition, and review of proofs. Errors that could affect the content may be 
corrected during these processes. 
Twinkle-associated familial parkinsonism with Lewy 
pathology: Cause or predisposition? 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Published Ahead of Print on August 26, 2020 as 10.1212/WNL.0000000000010674
  
 
1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland  
2Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, 
Scotland 
3Usher Institute of Population Health Sciences and Informatics, University of 
Edinburgh, Edinburgh, Scotland 
4Department of Laboratory Medicine, St Michael’s Hospital, Toronto, Canada 
5Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria 
Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada 
6Department of Medicine, University of Toronto, Toronto, Canada 
7Krembil Research Institute, Toronto Western Hospital, Toronto, Canada 
 
*Correspondence to: Prof Anthony E Lang, (Anthony.Lang@uhnresearch.ca) 
 
Supplemental Data 
video(compressed).mp4 
 
Manuscript word count: 969; Title character count: 86; Number of references: 14; 
Figures: 1; Tables: 1 
 
Keywords: Mitochondrial Disorders [96], Parkinson’s Disease/Parkinsonism [165], 
Twinkle, C10orf2, CPEO 
 
Study funding: No targeted funding reported. 
Disclosures: The authors report no disclosures relevant to the manuscript.  
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  
 
INTRODUCTION 
 
Mitochondrial dysfunction is a recognised cause of autosomal recessive Parkinson’s 
disease (PD) and may contribute to idiopathic disease.1 Twinkle protein is a DNA 
helicase coded by the C10orf2 gene which, along with polymerase gamma and other 
proteins, is responsible for regulating mitochondrial replication. Heterozygous 
C10orf2 mutations are a recognised cause of chronic progressive ophthalmoplegia 
(CPEO) and other neurological manifestations, but their relationship with 
parkinsonism is unclear. Here, we report a case (along with postmortem examination 
findings) of familial parkinsonism associated with a heterozygous mutation in 
C10orf2, alongside reviewing previously published cases.  
 
CASE REPORT 
 
A 61 year-old man was referred to our clinic with an 18-month history of left leg 
dragging and left arm motor dysfunction (e.g. difficulty putting hand in pocket). 
Family members commented that he had a softer voice and reduced facial expression. 
Non-fatigable bilateral eyelid ptosis was present on his driving licence three years 
earlier. His mother had been diagnosed with Parkinson’s disease (PD): she presented 
with shuffling gait and poor balance in her early 60s, responded well to levodopa but 
developed peak-dose dyskinesias, and died aged 79. 
 
Examination confirmed bilateral ptosis (palpebral fissures 8mm vertically and normal 
levator excursion) and a mild complex ophthalmoplegia. There was evidence of 
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parkinsonism (predominantly affecting the left hemibody), which improved with 
levodopa (Video,http://links.lww.com/WNL/B196). 
 
MR brain scan showed patchy small vessel ischaemic changes in the pons but no 
other abnormalities. Single fibre electromyogram was abnormal with mean jitter 
duration 47 microseconds (normal <36). Acetylcholine receptor antibodies were 
negative. POLG testing revealed no pathogenic mutations. Muscle biopsy was booked 
but the patient did not attend. A provisional diagnosis of PD with CPEO was made, 
although the possibility of a unifying aetiology related to mitochondrial dysfunction 
was considered. 
 
Over the next few years, additional medications (selegiline, entacapone and 
pramipexole) were sequentially added due to the development of motor fluctuations 
including mild generalised dyskinesias. Around seven years after diagnosis, he began 
to develop non-motor complications including cognitive decline, falls (ultimately 
requiring a walking frame), neuropsychiatric symptoms (visual hallucinations and 
paranoia) and swallowing difficulties. These progressively worsened despite 
medication alterations (pramipexole and selegiline stopped, rivastigmine and 
quetiapine started). He was eventually admitted to a nursing home and died 
approximately 10 years after diagnosis due to a presumed aspiration pneumonia.  
 
Just prior to his death, further genetic testing revealed a heterozygous variant in the 
C10orf2 gene on chromosome 10 (c.908G>A, p.[Arg303Gln]). Bioinformatic analysis 
predicted that this variant was pathogenic and had a very low allele frequency on 
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gnomAD (0.0012%). PD gene panel testing identified no other clinically relevant 
variants. 
 
Postmortem examination revealed severe, patchy neuronal cell loss in the substantia 
nigra with evidence of limbic (transitional) stage Lewy body disease according to the 
Montine classification (Figure).2 In the substantia nigra, alpha-synuclein 
immunostains labelled Lewy bodies and Lewy neurites, as well as diffusely filled 
perikarya. Lewy bodies were also present in the locus coeruleus, periaqueductal gray 
matter, basal temporal neocortex and cingulate gyrus (Figures C,D,H); but sparse in 
other regions of the neocortex. There were no abnormalities in the cerebellum. There 
was no significant deposition of tau, beta-amyloid or TDP-43 proteins. 
 
DISCUSSION 
 
We propose that heterozygous C10orf2 mutations may be a rare cause of 
parkinsonism and should be considered in patients with a positive family history 
and/or other features of a mitochondrial disorder (e.g. CPEO). We searched the 
literature and found eight previously reported cases of parkinsonism associated with 
heterozygous C10orf2 mutations (Table).3-7 They are unlikely to be a major 
contributor to overall PD heritable risk; indeed, C10orf2 does not appear as a risk loci 
on the most recent meta-analysis of genome-wide association studies.8 
 
We cannot exclude the possibility that the association may be a coincidence, 
especially since we were unable to perform segregation analysis. Unfortunately, only 
fixed brain tissue was available for the post-mortem examination which precluded 
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molecular analysis (such as mtDNA deletion load). In the single reported autopsy case 
of a patient with heterozygous C10orf2 mutation, there was also significant loss of 
substantia nigra neurons (even though the patient did not have clinical evidence of 
parkinsonism), but no Lewy bodies were present (unlike our case).9 We hope that 
neuropathological analysis of future cases will help to determine the precise 
pathological underpinnings of parkinsonism in heterozygous C10orf2 mutation 
carriers. 
 
Twinkle protein is important for maintaining mtDNA integrity. In a mouse model 
expressing mutant Twinkle, there was accelerated accumulation of mtDNA deletions 
and loss of TH-positive neurons (leading to motor impairment).10 Patients with 
biallelic C10orf2 mutations typically present with severe and complex neurological 
phenotypes (e.g. infantile-onset spinocerebellar ataxia, epilepsy, sensory 
polyneuropathy, Perrault syndrome, adult-onset mitochondrial myopathy) alongside 
systemic features, but not parkinsonism. The classical pathology in these patients 
includes severe neuronal loss in the substantia nigra in the absence of Lewy bodies or 
alpha-synuclein deposition, often accompanied by degeneration of the cerebellar-
dentato-olivary system. Further studies are required to explain why most patients with 
biallelic C10orf2 mutations do not exhibit parkinsonism despite demonstrating severe 
substantia nigra neuronal loss (which also occurs with biallelic POLG mutations).9 
 
Heterogeneous neuropathology is a recognised feature of genetic PD associated with 
mitochondrial dysfunction. A review of autopsy findings in 18 homozygous or 
compound heterozygous Parkin cases found Lewy bodies in only 6 patients, despite 
evidence of neuronal loss in the substantia nigra in all cases.11 In the two postmortem 
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cases of biallelic PINK1 mutations, Lewy bodies were present in one12 and absent in 
the other.13 The role of heterozygous Parkin and PINK1 mutations is controversial, 
however it is intriguing that the limited number of autopsy studies have shown diffuse 
Lewy bodies in both groups. This may support the concept of genetic predisposition 
to PD by the mitochondrial dysfunction caused by these heterozygous states, which is 
in line with a recent report showing greater Lewy body pathology in older patients 
with mitochondrial dysfunction due to a range of nuclear and mtDNA genetic 
defects.14 
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FIGURE TITLE: Neuropathology of Twinkle-associated parkinsonism 
 
FIGURE LEGEND 
 
A. Low power view of the substantia nigra showing patchy loss of neurons, with areas 
of complete loss (green circle) contrasting with others of partial preservation (yellow 
circle), bar 800 µm. Luxol Fast Blue (LFB) staining on hematoxylin and eosin. 
B. Substantia nigra immunostained for alpha synuclein showing Lewy bodies (blue 
arrows), Lewy neurites (red arrows), and neurons with cytoplasm diffusely filled with 
alpha synuclein (green arrows), bar 200 µm. The inset shows Lewy bodies (blue 
arrows) in two neurons on LFB staining, bar 100 µm (applies to all insets). 
C. Locus coeruleus immunostained for alpha synuclein, bar 200 µm. The inset shows 
Lewy bodies on LFB staining (blue arrow). 
D. Periaqueductal gray (aqueduct at center bottom) immunostained for alpha 
synuclein showing labelled neurons with Lewy bodies (inset, blue arrow), bar 2 mm. 
E. Putamen immunostained for alpha synuclein showing Lewy neurites (blue arrow), 
bar 200 µm. 
F. Hippocampus immunostained for alpha synuclein showing labelling in the CA2 
sector (blue arrow), bar 2.5 mm 
G. Higher power view of the alpha synuclein immunostained CA2 area of the 
hippocampus showing predominantly horizontally oriented Lewy neurites, bar 200 
µm. 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  
H. Temporal neocortex immunostained for alpha synuclein showing scattered cortical 
Lewy bodies (blue arrows), bar 200 µm. 
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 TABLE: Previously reported cases of parkinsonism associated with heterozygous C10orf2 mutations 
 
Ref/case Sex Onseta Family 
history 
MR scan DAT scan Muscle 
biopsy 
Levodopa 
response 
Mutation 
3/III-3 F Early 
50s 
Yes NR NR NR NR R374Q 
3/III-2 F 41 Yes Normal NR Abnormal Yes R374Q 
3/III-4 F Early 
40s 
Yes NR NR NR Yes R374Q 
4/ F 57 Yes Lacunar infarct in basal 
ganglia 
NR NR No A475T 
5/III-1 M 50 Yes Normal Abnormal Normal Not treated R334Q 
6/ M 70 No Non-specific white matter 
lesions 
Abnormal Abnormal Not treated A303T 
7/II-2 F Early 
80s 
Yes Mild white matter changes Abnormal NR Yes G1750A 
7/II-3 F 77 Yes NR Abnormal Abnormal Not treated G1750A 
 
aAge of onset of parkinsonism, bOne of more first-degree family member. MR=magnetic resonance, DAT=dopamine transporter, M=male, 
F=female, NR=not reported. All cases had CPEO which began 1-2 decades prior to their parkinsonism (three cases underwent corrective eye 
surgery), with one exception where the patient had childhood-onset ptosis. Similar numbers of males and females were affected and the majority 
had a positive family history. Dopamine transporter imaging was universally abnormal when it was performed, whilst 3 out of 5 MR brain scans 
showed white matter abnormalities. Muscle biopsy tended to be abnormal when it was performed (with mitochondrial changes including COX 
negative fibres and mtDNA deletions) but one was normal. Most patients responded to levodopa when it was initiated, although limited 
information was available on progression of symptoms. Brain postmortem assessment was not performed in any of these cases.AC
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VIDEO LEGEND 
 
 
Examination took place a few years after he presented to our clinic. He was taking 
levodopa (total daily dose 800mg) and his parkinsonian signs were less marked. The 
video shows evidence of bilateral ptosis with mild restriction of eye movements 
(particularly upgaze). There was no improvement on vestibulo-ocular reflex testing 
(not shown). There was very mild bradykinesia in the limbs, along with mild 
choreiform movements. Gait was fairly normal apart from a slight lean to the right 
and mild impairment on tandem walking. 
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